论文部分内容阅读
常用的肾脏放射性药物~(99m)Tc-DTPA和~(131)Ⅰ马尿盐酸均有明显的缺点。~(99m)Tc-DTPA通过肾小球滤过被排除,因此它在肾脏中的摄取效率只有20～25%。~(131)Ⅰ马尿酸盐主要通过管状细胞分泌排除,在肾脏中摄取效率较高,大约65～80%。但~(131)Ⅰ标记限制了显象的空间分辨率。常规使用的理想的肾脏放射性药物,应该是~(99m)Tc标记并具高摄取效率。好的萃取只能通过管状细胞分泌排除来达到。由管状细胞排泄的N,N′-双(巯基乙酰基)-乙二胺~(99m)Tc(~(99m)Tc-DADS)的发现,在
Commonly used renal radiopharmaceuticals ~ (99m) Tc-DTPA and ~ (131) I-malachite have obvious shortcomings. ~ (99m) Tc-DTPA is excluded by glomerular filtration and therefore its uptake efficiency in the kidney is only 20-25%. ~ (131) I hippurate is mainly secreted by tubular cells and has a high uptake efficiency in the kidney of about 65-80%. However, the ~ (131) I marker limits the spatial resolution of imaging. The ideal kidney-use radiopharmaceutical for routine use should be ~ (99m) Tc-labeled with high uptake efficiency. Good extraction can only be achieved through the secretion of tubular cells. The discovery of N, N’-bis (mercaptoacetyl) -ethylenediamine ~ (99m) Tc (~ (99m) Tc-DADS)